Credit Suisse analyst Matthew Keeler said St. Jude Medical shares are likely to remain under pressure until it provides a detailed commentary on Muddy Waters allegations of vulnerabilities in its cardiac rhythm management remote monitoring system. The analyst said the the breaches described in the report are not likely to result in the removal of St. Jude's products from the US market given that there have been no related patient events to date, but if the FDA believes more widespread attacks are possible and St. Jude is vulnerable, he foresees significant downside to shares. Keeler rates St. Jude a Neutral with an $81 price target.